{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000138","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.107420+00:00","generated_at":"2026-05-17T00:12:43.050758+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M","bullets":["Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).","ANKTIVA unit volumes up 467% YTD 2025 vs FY2024; net loss attributable to common $67.3M (vs $85.7M).","Cash and securities $257.8M at Sep 30, 2025, up from $153.7M at Jun 30, 2025.","Early glioblastoma combo study: 100% disease control (2 near-complete responses, 3 stable).","Phase 3 NSCLC trial (ResQ201A) initiated; ANKTIVA named preferred drug by ~80M-life organization."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000138","json":"https://secwatch.observer/filing/0001326110-25-000138.json","markdown":"https://secwatch.observer/filing/0001326110-25-000138.md","text":"https://secwatch.observer/filing/0001326110-25-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/0001326110-25-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:12:43.050758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}